PFREUNDSCHUH PETER P.

SEC source: 0001585839-25-000004 · form4-09192025_010937.xml · derivative · entry 5

PFREUNDSCHUH PETER P. · CIK 0001585839 · EVP, CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,900 shares

Expires not disclosed

F5 · security: Performance-Based RSUs ("PRSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each PRSU represents a contingent right to receive one share of Common Stock on the vesting dates of the PRSU.

F6 · derivative.exercise_price: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F6 · price: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

F6 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

F6 · derivative.expiration_date: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

SEC source: 0001585839-25-000004 · form4-09192025_010937.xml · derivative · entry 4

PFREUNDSCHUH PETER P. · CIK 0001585839 · EVP, CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,900 shares

Expires not disclosed

F5 · security: Performance-Based RSUs ("PRSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each PRSU represents a contingent right to receive one share of Common Stock on the vesting dates of the PRSU.

F6 · derivative.exercise_price: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F6 · price: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

F6 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

F6 · derivative.expiration_date: At the Effective Time, pursuant to the Merger Agreement, each PRSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the maximum number of Shares issuable in settlement of such PRSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.

SEC source: 0001585839-25-000004 · form4-09192025_010937.xml · derivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · EVP, CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 63,500 shares

Expires 2035-01-17

F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F4 · price: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.

SEC source: 0001585839-25-000004 · form4-09192025_010937.xml · derivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · EVP, CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 170,000 shares

Expires 2034-07-12

F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F4 · price: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.

SEC source: 0001585839-25-000004 · form4-09192025_010937.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · EVP, CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU.

F3 · price: At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration").

SEC source: 0001415889-25-001879 · form4-01232025_120151.xml · derivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,500

Underlying: Common Stock · 63,500 shares

Expires 2035-01-17

F2 · security: Represents stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.

F3 · derivative.exercise_date: The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2026, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-25-001879 · form4-01232025_120151.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,800

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2026, January 17, 2027 and January 17, 2028, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-019529 · form4-07122024_090750.xml · derivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2034-07-12

F2 · security: Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.

F3 · derivative.exercise_date: The stock options shall vest and become exercisable as to 25% of the shares subject to the option on July 12, 2025, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-019529 · form4-07122024_090750.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,000

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSU. The RSUs vest by 1/3 on each of July 12, 2025, July 12, 2026 and July 12, 2027, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001104659-24-026556 · tm246990-2_4seq1.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,669

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2024. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.54, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-24-024981 · tm246517-1_4seq1.xml · derivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-02-09

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-024981 · tm246517-1_4seq1.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,433

F1 · shares: Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-23-107217 · tm2327817-1_4seq1.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,433

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 1, 2023. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 1, 2023. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.24, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-23-024422 · tm237526-3_4seq1.xml · derivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 76,000 shares

Expires 2033-02-17

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 17, 2023. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-23-024422 · tm237526-3_4seq1.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,000

F1 · shares: Consists of shares of common stock issuable under an aggregate of 38,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 17, 2023. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-22-105844 · tm2227394-1_4seq1.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · shares: Consists of shares of common stock underlying a restricted stock unit ("RSU") award. Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is October 1, 2022. The RSU award vests over three years, with 33.333% of the shares of common stock underlying the RSU award vesting upon the one-year anniversary of such vesting commencement date and the remainder vesting in equal annual installments thereafter, subject to the Reporting Person's continued service as an employee.

SEC source: 0001104659-22-101958 · tm2226340-3_4seq1.xml · derivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-09-19

F1 · shares: This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · derivative.exercise_date: The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.

SEC source: 0001127602-22-006327 · form4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,927

F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.40 to $3.76. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001127602-22-006327 · form4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,469

F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.79 to $3.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001127602-22-005755 · form4.xml · derivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F5 · derivative.exercise_date: The restricted stock units will fully vest on July 4, 2023.

F5 · derivative.expiration_date: The restricted stock units will fully vest on July 4, 2023.

SEC source: 0001127602-22-005755 · form4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,873

F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.00 to $4.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001127602-22-005755 · form4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,169

F1 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.29 to $4.54. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001127602-22-005327 · form4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,398

F3 · shares: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units and does not represent discretionary trades by the Reporting Person.

F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.28 to $4.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

SEC source: 0001127602-22-005327 · form4.xml · derivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F5 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

SEC source: 0001127602-22-005327 · form4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · balance_after: Includes 745 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2021.

SEC source: 0001127602-21-014291 · form4.xml · derivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

SEC source: 0001127602-21-001981 · form4.xml · derivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-01-14

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025.

SEC source: 0001127602-20-030495 · form4.xml · derivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,000

Underlying: Common Stock · 230,000 shares

Expires 2030-12-01

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on December 1, 2021 and in equal monthly installments on the same day of each month thereafter and will be fully vested and exercisable on December 1, 2024.

SEC source: 0001209191-20-055037 · doc4.xml · derivative · entry 7

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Ordinary Shares · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F5 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 5,000 ordinary shares. Under the original terms of the agreement, 33.33% of the RSUs will vest on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

F5 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 5,000 ordinary shares. Under the original terms of the agreement, 33.33% of the RSUs will vest on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

SEC source: 0001209191-20-055037 · doc4.xml · derivative · entry 6

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,082

Underlying: Ordinary Shares · 2,084 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F4 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 5,000 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

F4 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 5,000 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

SEC source: 0001209191-20-055037 · doc4.xml · derivative · entry 5

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,667

Underlying: Ordinary Shares · 833 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

SEC source: 0001209191-20-055037 · doc4.xml · nonDerivative · entry 4

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,405

F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

SEC source: 0001209191-20-055037 · doc4.xml · nonDerivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,422

F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

SEC source: 0001209191-20-055037 · doc4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,829

F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

SEC source: 0001209191-20-055037 · doc4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0001209191-20-048883 · doc4.xml · derivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,166

Underlying: Ordinary Shares · 1,042 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

SEC source: 0001209191-20-048883 · doc4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,888

F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

SEC source: 0001209191-20-048883 · doc4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,397

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0001209191-20-043874 · doc4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,355

F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

SEC source: 0001209191-20-043874 · doc4.xml · derivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Ordinary Shares · 417 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

SEC source: 0001209191-20-043874 · doc4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0001209191-20-030900 · doc4.xml · derivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,208

Underlying: Ordinary Shares · 1,041 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

SEC source: 0001209191-20-030900 · doc4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,079

F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

SEC source: 0001209191-20-030900 · doc4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,437

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0001209191-20-025903 · doc4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,396

F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

SEC source: 0001209191-20-025903 · doc4.xml · derivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,917

Underlying: Ordinary Shares · 417 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

SEC source: 0001209191-20-025903 · doc4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,537

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0001209191-20-012017 · doc4.xml · derivative · entry 3

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,249

Underlying: Ordinary Shares · 1,042 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F4 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

F4 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on July 19, 2018 representing 12,500 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.

SEC source: 0001209191-20-012017 · doc4.xml · nonDerivative · entry 2

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,120

F3 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

SEC source: 0001209191-20-012017 · doc4.xml · nonDerivative · entry 1

PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F2 · balance_after: This amount includes 1,000 shares reported on Reporting Person's Form 3 that were omitted from subsequent Form 4 filings.